Data as of Oct 30
| +2.70 / +6.21%|
The 29 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 50.97, with a high estimate of 61.47 and a low estimate of 32.43. The median estimate represents a +10.29% increase from the last price of 46.21.
The current consensus among 30 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.